Cannabis Intoxication Case Series: The Dangers of Edibles Containing Tetrahydrocannabinol

Vo, Kathy T.; Horng, Howard; Li, Kai; Ho, Raymond; Wu, Alan H.B.; Lynch, Kara L.; Smollin, Craig G.

doi:10.1016/j.annemergmed.2017.09.008

Cited by 39 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increasing availability of marijuana edibles, including hemp oil, candy, popcorn, and beverages has been associated with increased ED visits. Sometimes adults and children are not aware of the ingredients of the food they consume (20).…”

Section: Discussionmentioning

confidence: 99%

“…The patient was prescribed benzodiazepine and discharged. Withdrawal symptoms are documented as agitation, anxiety, mood swings, tremor, palpitation, diaphoresis (sweating), hypertension, hyperventilation, headache, nausea and vomiting (20,21).…”

Section: Discussionmentioning

confidence: 99%

“…The most common presenting symptoms among patients on admission were unstable cognitive conditions (drowsiness, clouding of consciousness, confusion and secondary aggression, anxiety and restlessness) and tachycardia. Only one patient had The mean duration of the observation was 11.5(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) hours. No mortality was observed.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Identification of Substance Abuse Among Children in a Pediatric Emergency Department

Çiftdemir¹,

Eren²,

Karal³

2020

jpr

View full text Add to dashboard Cite

Illicit substance use is a worldwide important public health problem with increasing substance abuse rates and decreasing starting age. In this study, our aim was to determine the complaints of the patients in pediatric emergency department (PED) admission in order to increase awareness about substance abuse. Materials and Methods: The data of this cross-sectional study was gathered from those patients admitted to a PED with complaints of substance abuse and patients without a history of substance abuse, but with a positive urine drug test. A screening urine test was used for the qualitative determination of drug substances. If positive, a quantitative liquid chromatography integrated mass/mass spectrometry test was ordered for confirmation. Results: A total of 17 patients presented to the emergency department. The most frequent symptoms were unstable cognitive conditions and tachycardia. Laboratory analyses showed high creatine kinase-MB. Synthetic cannabinoids were the most frequently detected substance in urine screening and confirmation tests. Twenty-nine percent of patients were hospitalized and no mortality was observed. Conclusion: The use of illegal substances has increased in teenagers. Emergency department doctors must be informed and trained regarding substance abuse since patients frequently presented to the emergency department with cognitive malfunctions. Also, it should be remembered that patients may present with symptoms concerning various organ systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of Substance Abuse Among Children in a Pediatric Emergency Department

Çiftdemir¹,

Eren²,

Karal³

2020

jpr

View full text Add to dashboard Cite

show abstract

“…There is growing awareness of vaping‐associated pulmonary injury and mortality, and up to 40% of medical cannabis users report vaping as a route of administration . Finally, high‐potency edible cannabis has been associated with altered mentation …”

Section: Cannabis: Indications Use Versus Evidence Basementioning

confidence: 99%

Medical cannabis use among individuals with cancer: An unresolved and timely issue

Nugent

Meghani

Rogal

et al. 2020

Cancer

View full text Add to dashboard Cite

The role of cannabis in cancer care is a complex and challenging issue. Cancer and its treatments currently are designated as qualifying conditions in the majority of the 33 states that now have legalized medical cannabis. 1 Consequently, cannabis use in patients with cancer is common: nearly one-quarter of individuals with cancer report current cannabis use 2,3 and >90% of cancer survivors view cannabis as potentially beneficial for symptom management and support its legalization. 4 Recent studies have suggested that physicians may be more likely to recommend cannabis to patients with cancer compared with patients with other serious illnesses, 5 and that oncologists are becoming increasingly accepting of patients using cannabis, despite their continued concerns regarding its safety and efficacy. 6,7 For example, approximately 46% of oncologists reported recommending medical cannabis clinically and approximately 80% discussed it with their patients, despite the fact that approximately 70% acknowledged that they were insufficiently educated regarding medical cannabis. 8 Thus, there appears to be a disconnect between medical cannabis's legal status and high acceptance by patients, recommendations from clinicians, and a poor evidence base concerning its safety and efficacy.A more complete and nuanced understanding of the relevant issues is imperative in this current climate of growing cannabis availability and acceptance. In this commentary, we have discussed key clinical issues related to the efficacy and safety of cannabis in patients with cancer and noted important lingering questions for clinical practice and research in this area. Cannabis: Indications, Use Versus Evidence BaseApproximately 75% of individuals with cancer use cannabis for symptom management, most commonly pain, nausea, and sleep disruption 9,10 ; however, to the best of our knowledge, the evidence base supporting this has been limited. It is important to note at the outset that the majority of the cannabis research conducted in oncology patients lacks the rigor that would be required of most other oncology treatments in practice. Even the limited number of randomized controlled trials that exist for comparing the efficacy of cannabis with that of placebo or other drugs in oncologic patients are homogeneously low or very low in quality. 11 A recent systematic review characterized the available evidence regarding cannabis for cancer symptom management as low quality and found no benefit for its common indications of pain, sleep, or a reduction of opioid dose. 12 In addition, to our knowledge, evidence for the antiemetic properties of plantbased preparations is seriously lacking. In effect, the best evidence exists for oral, pharmaceutically prepared, synthetic tetrahydrocannabinols (THCs) such as nabilone and dronabinol, which have been found to be superior to placebo and equivalent to other antiemetic medications. [13][14][15] For example, one observational prospective study found at least a 30% reduction in symptoms such as vomiting and fatigue ...

show abstract

“…Social acceptance fostered by celebrity endorsement, as an example, can alter how an ingredient is perceived. In the case of cannabis, the association between health and benefits has been building slowly over the years which could have categorized cannabis as a medication, and not a general food ingredient (Vo et al, 2018). As a result, to broaden the market of edibles can be challenging.…”

Section: Figure 1 Dimensions To a Balanced Between Polity And Socialmentioning

confidence: 99%

Getting Healthy Without Getting High: Lexaria’s Approach to Cannabinoids

Charlebois¹

2018

JFS

View full text Add to dashboard Cite

The legalization of cannabis in Canada has been a controversial issue. Over the last few years most of the attention has been on the production and distribution of cannabis. As the public discourse on cannabis matured, the drug and inherent benefits remained misunderstood by industry, policymakers, and consumers alike. Lexaria Bioscience, a British Columbia-based licensing company in Canada, is attempting to change how we market edibles in Canada and elsewhere. This case study first looks at the market of cannabis in general. It then describes how the company began to investigate cannabinoids. Based on interviews conducted with key informants in the company, some key elements of Lexaria’s business model were isolated, including their challenges. The company argues that many people want to consume edibles without the psychoactive effects of THC. This case study attempts to conceptualize what the state of the market should look like to accommodate Lexaria’s technologies and the commercialization of edibles. A discussion on the case is presented and future research paths on edible research are suggested

show abstract

Cannabis Intoxication Case Series: The Dangers of Edibles Containing Tetrahydrocannabinol

Cited by 39 publications

References 17 publications

Identification of Substance Abuse Among Children in a Pediatric Emergency Department

Identification of Substance Abuse Among Children in a Pediatric Emergency Department

Medical cannabis use among individuals with cancer: An unresolved and timely issue

Getting Healthy Without Getting High: Lexaria’s Approach to Cannabinoids

Contact Info

Product

Resources

About